Publications by authors named "Naoki Taka"

Claim this Profile
D
Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
Hirosato Ebiike, Naoki Taka, Masayuki Matsushita, Masayuki Ohmori, Kyoko Takami

J Med Chem· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi, Toshihiko Fujii, Kiyoaki Sakata, Naoki Taka

Mol Cancer Ther· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Yoshihito Ohtake, Tsutomu Sato, Takamitsu Kobayashi, Masahiro Nishimoto, Naoki Taka, Koji Takano, Kyoko Takami

J Med Chem· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Yoshihito Ohtake, Tsutomu Sato, Hiroharu Matsuoka, Takamitsu Kobayashi, Masahiro Nishimoto, Naoki Taka, Koji Takano, Takashi Higuchi

Bioorg Med Chem· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5a-Carba-β-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Yoshihito Ohtake, Tsutomu Sato, Hiroharu Matsuoka, Masahiro Nishimoto, Naoki Taka, Koji Takano, Takashi Higuchi, Takamitsu Kobayashi

Bioorg Med Chem· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel motilin antagonists: Conversion of tetrapeptide leads to orally available peptidomimetics.
Naoki Taka, Hiroharu Matsuoka, Tsutomu Sato, Hitoshi Yoshino, Ikuhiro Imaoka

Bioorg Med Chem Lett· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel platinum compound inhibits telomerase activity in vitro and reduces telomere length in a human hepatoma cell line.
Miho Furuta, Katsura Nozawa, Masaharu Takemura, Shunji Izuta, Takashi Murate, Naoki Taka

Int J Cancer· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis